A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer
Karen Urtishak, Anuradha Jayaram, Ligi Mathews, Nicholas A. Zorko et al.
Citations
1 citations
Journal
Cancer Chemotherapy and Pharmacology
Topics
Prostate Cancer Treatment and Research
Field-Weighted Citation Impact (FWCI)
36.44
article
A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer
Karen Urtishak, Anuradha Jayaram, Ligi Mathews, Nicholas A. Zorko, Peter Francis, D. Ghosh, Brent Rupnow, Kevin Zarrabi, Edward F. Attiyeh, Johann Sebastian De Bono, Sherry Wang, Andrew Hudson, Mengjie Li, Benjamin Garmezy
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Cancer Chemotherapy and PharmacologyVol. 96(1)
Institutions
University of Minnesota (US), Royal Marsden NHS Foundation Trust (GB), Johnson & Johnson (United States) (US), Thomas Jefferson University Hospital (US), Sarah Cannon (US), The Christie NHS Foundation Trust (GB)